PubMedCentralPubMedCrossRef 15 Ojwang JO, Buckheit RW, Pommier Y

PubMedCentralPubMedCrossRef 15. Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Este JA, Reymen D, Pallansch LA, Lackman-Smith C, Wallace TL, et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and

clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1995;39:2426–35.PubMedCentralPubMedCrossRef 16. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, click here Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646–50.PubMedCrossRef 17. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology. 2008;5:114.PubMedCentralPubMedCrossRef 18. Li X, Krishnan L, Cherepanov P, Engelman A. Structural biology of retroviral

AZD1480 mouse DNA integration. Virology. 2011;411:194–205.PubMedCentralPubMedCrossRef 19. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Selleck Momelotinib Microbiol. 2012;10:279–90.PubMedCentralPubMedCrossRef 20. Waters LJ, Barber TJ. Dolutegravir for treatment of HIV: SPRING forwards? Lancet. 2013;381:705–6.PubMedCrossRef 21. Wills T, Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs. 2012;21:395–401.PubMedCrossRef 22. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs. 2012;21:523–30.PubMedCrossRef 23. Wainberg MA, Quashie PK, Mesplede T. Dolutegravir HIV integrase inhibitor treatment of HIV infection. Drug Future. 2012;37:697–707. 24. Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, Amino acid DiNubile MJ, et al. Durable efficacy and safety of raltegravir versus efavirenz when

combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63:77–85.PubMedCrossRef 25. Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vezinet F, Plantier JC, Descamps D. In-vitro phenotypic suscept 1 ‘non b’ integrase inhibitors naive clinical isolates to dolutegravir and raltegravir. AIDS. 2013;27(18):2959–2961. 26. Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses. 2009;25:225–7.PubMedCrossRef 27. Messiaen P, Wensing AM, Fun A, Nijhuis M, Brusselaers N, Vandekerckhove L. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS ONE. 2013;8:e52562.PubMedCentralPubMedCrossRef 28. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, et al.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>